BioNTech SE (BNTX) Stock News
$BNTX · NASDAQ · 1 stories in 30 days$87.61
1D −2.87%1W +0.06%1M +0.58%
BORSA has published 1 story on BioNTech SE (BNTX) in the past 30 days. BORSA’s news read on BNTX is bearish at 35/100, unchanged over 24 hours, based on 1 company event over the past 7 days. BNTX last closed at $96.96 on Oct 9, up 0.06% over five sessions and up 0.58% over the past month. BioNTech SE’s next earnings report is scheduled for Tuesday, Nov 3 before the open.
The wire on $BNTX
newest first · updated · direct subject stories onlyBioNTech BNT113 trial misses PFS endpoint, continues for overall survival
BioNTech's Phase 2/3 trial for BNT113 plus pembrolizumab missed the PFS endpoint in HPV16+ head and neck cancer. The trial continues for the OS endpoint, which could still yield a positive outcome.
bearish 30 · impact 60